Search Results

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 3,500 shares of the Company’s common stock at an exercise price per share of $16.41, which was the closing price on June 24, 2024, and restricted stock units to acquire a total of 1,750 shares of the Company’s common stock.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 36,100 shares of the Company’s common stock at an exercise price per share of $16.09, which was the closing price on June 10, 2024, and restricted stock units to acquire a total of 18,050 shares of the Company’s common stock.

Arcus Biosciences announced that its management team will participate in a fireside chat at the upcoming Bank of America Healthcare Conference in Las Vegas, NV.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 16,300 shares of the Company’s common stock at an exercise price per share of $16.28, which was the closing price on May 23, 2024, and restricted stock units to acquire a total of 8,150 shares of the Company’s common stock.

Arcus Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis, HIF-2a, AXL and PD-1 – across multiple common cancers.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted 17 new employees options to purchase a total of 141,100 shares of the Company’s common stock at an exercise price per share of $15.26, which was the closing price on May 8, 2024, and restricted stock units to acquire a total of 70,555 shares of the Company’s common stock.